MENU CONTENTS

Developments

Successful Commercialization of
the World’s First Allogeneic Stem Cell Drug

MEDIPOST has successfully commercialized CARTISTEM®, the World’s First Allogeneic Stem Cell Drug, and
has been conducting clinical trials of the therapeutics drugs for Bronchopulmonary Dysplasia (BPD)
and Alzheimer’s Disease (AD)

CARTISTEM®

  • Korean market-approval
  • Phase 1/2a clinical trial in U.S.
  • Research
  • Non-Clinical
  • IND
  • Clinical
  • BLA
  • Launch
  • Korean market-approval

  • Phase 1/2a clinical trial in U.S.

PNEUMOSTEM®

  • Phase 2 clinical trial in Korea
  • Phase 1/2 clinical trial in U.S.
  • Orphan Drug Designation in U.S. and E.U.
  • Research
  • Non-Clinical
  • IND
  • Clinical
  • BLA
  • Launch
  • Phase 2 clinical trial in Korea

  • Phase 1/2 clinical trial in U.S.

NEUROSTEM®

  • Ongoing Phase 1/2a clinical trial in Korea
  • Expected submission of FDA IND
    for clinical trial in U.S.
  • Research
  • Non-Clinical
  • IND
  • Clinical
  • BLA
  • Launch
  • Ongoing Phase 1/2a clinical trial (KR)

상단으로